Enhabit Reports First Quarter 2023 Financial Results and Reaffirms Full-Year Guidance

Enhabit Reports First Quarter 2023 Financial Results and Reaffirms Full-Year Guidance

May 09, 2023 | Last Trade: US$7.56 0.09 1.20

NYSE: EHAB

Healthcare

Healthcare Services

Financial Results

VISIT WEBSITE

Announces new national payor agreement and two new convener agreements with national reach effective May 1, 2023
Company to host a conference call tomorrow, May 10, 2023 at 10 AM EDT

DALLAS / May 09, 2023 / Business Wire / Enhabit, Inc. (NYSE: EHAB), a leading home health and hospice care provider, today reported its results of operations for the first quarter ended March 31, 2023.

“The first quarter was underscored by progress in two of our critical success factors for 2023. Our sequential admissions growth for home health and hospice was possible due to our continued efforts in recruitment and retention of clinical staff and our payor innovation team negotiating a new national payor agreement and two convener agreements with national reach,” said Enhabit’s President and Chief Executive Officer, Barb Jacobsmeyer. “With our expansion of Medicare Advantage contracts and improved rates combined with reduced staffing capacity constraints, we expect to see improvements in our bottom line throughout 2023.”

QUARTERLY PERFORMANCE - CONSOLIDATED

Net service revenue of $265.1 million
Net income of $3.2 million
Adjusted EBITDA of $25.3 million
Earnings per diluted share of $0.05
Adjusted earnings per diluted share of $0.09

RECENT COMPANY HIGHLIGHTS

Executed new national agreement with Medicare Advantage payor plus two new agreements with conveners with national reach
Continued strong growth in home health Medicare Advantage admissions with non-episodic admissions up 31.9% driving total admissions growth of 1.2% year over year
Continued recruiting success adding 101 net new full-time nursing hires in the first quarter
Further reduced staffing constrained hospice locations with continued implementation of case management model for nurses; hospice staffing constraints lowest in four quarters
Acquired one home health location in Indiana and opened two de novo hospice locations in Texas in March

FINANCIAL RESULTS

Consolidated

	Q1										*'23 vs. '22*
*($ in millions, except per share data)*	2023					2022					*'23 vs. '22*
Home health net service revenue	$			215.8		$			224.9		(4.0	)%
Hospice net service revenue				49.3					49.4		(0.2	)%
Total net service revenue	$			265.1		$			274.3		(3.4	)%

	% of Revenue					% of Revenue
Cost of services	50.0	%	$	(132.6	)	47.3	%	$	(129.7	)	2.2	%
Gross margin	50.0	%		132.5		52.7	%		144.6		(8.4	)%
General and administrative expenses	40.2	%		(106.7	)	35.3	%		(96.9	)	10.1	%
Operating expenses	90.2	%	$	(239.3	)	82.6	%	$	(226.6	)	5.6	%

Equity earnings / noncontrolling interests				0.5					0.6
Adjusted EBITDA	$			25.3		$			47.0		(46.2	)%
*Adjusted EBITDA margin*				*9.5*	%				*17.1*	%
Adjusted EPS	$			0.09		$			0.56		(83.9	)%

The continued shift to more non-episodic admissions in home health and the resumption of sequestration reduced consolidated net service revenue and adjusted EBITDA approximately $10 million year over year.

Adjusted EBITDA decreased year over year primarily due to the continued shift to more non-episodic admissions in home health, the resumption of sequestration, and increased general and administrative expenses. General and administrative expenses were higher year over year primarily due to an increase in employee group medical claims, approximately $2 million of incremental costs associated with being a stand-alone company, vendor rebates received in the first quarter of 2022, and improved back office staffing in the field.

SEGMENT RESULTS

Home health

	Q1						*'23 vs. '22*
*($ in millions)*	2023			2022			*'23 vs. '22*
Net service revenue	$	215.8		$	224.9		(4.0	)%
Cost of services	$	108.2			108.0		0.2	%
Gross margin		49.9	%		52.0	%
General and administrative expenses	$	62.9		$	58.7		7.2	%
Non-controlling interest	$	0.4		$	0.5		(20.0	)%
Adjusted EBITDA	$	44.3		$	57.7		(23.2	)%
% Adj. EBITDA margin		20.5	%		25.7	%
Operational metrics (Actual Amounts)
Starts of care
Episodic admissions		35,032			38,971		(10.1	)%
Non-episodic admissions		18,911			14,338		31.9	%
Total admissions		53,943			53,309		1.2	%
Same-store total admissions growth							—	%
Episodic recertifications		23,674			25,808		(8.3	)%
Non-episodic recertifications		8,104			5,979		35.5	%
Total recertifications		31,778			31,787		—	%
Same-store total recertifications growth							(0.5	)%
Total starts of care		85,721			85,096		0.7	%
Completed episodes		57,827			63,111		(8.4	)%
Revenue per episode	$	2,943		$	3,038		(3.1	)%
Visits per episode		14.8			15.2		(2.6	)%
Total visits		1,205,700			1,228,084		(1.8	)%
Non-episodic visits		351,283			270,253		30.0	%
Cost per visit	$	88		$	86		2.3	%

The year-over-year decrease in revenue was due primarily to the continued payor mix shift to more non-episodic admissions and the resumption of sequestration. Revenue per episode decreased year over year primarily due to the resumption of sequestration and the timing of completed episodes partially offset by a 0.7% increase in Medicare reimbursement rates.

Adjusted EBITDA decreased year over year primarily due to lower revenue and increased general and administrative expenses. General and administrative expenses increased primarily due to an increase in employee group medical claims, vendor rebates received in the first quarter of 2022, and improved back office staffing in the field. Cost per visit increased year over year primarily due to merit and market rate increases for clinical staff, increased contract labor, and increased costs associated with employee group medical claims partially offset by improved clinical productivity.

Hospice

	Q1						'23 vs. '22
*($ in millions)*	2023			2022			'23 vs. '22
Net service revenue	$	49.3		$	49.4		(0.2	)%
Cost of services	$	24.4			21.7		12.4	%
Gross margin		50.5	%		56.1	%
General and administrative expenses	$	16.3		$	14.9		9.4	%
Non-controlling interest	$	0.1		$	0.1		—	%
Adjusted EBITDA	$	8.5		$	12.7		(33.1	)%
% Adj. EBITDA margin		17.2	%		25.7	%
Operational metrics (Actual Amounts)
Total admissions		3,122			3,246		(3.8	)%
Same-store total admissions growth							(11.3	)%
Patient days		317,027			319,834		(0.9	)%
Discharged average length of stay		114			108		5.6	%
Average daily census		3,523			3,554		(0.9	)%
Revenue per day	$	155		$	154		0.6	%
Cost per day	$	77		$	68		13.2	%

Net service revenue was relatively flat to the prior year as the decline in average daily census and resumption of sequestration was offset by increased Medicare reimbursement rates. Admissions decreased 3.8% year over year but increased 7.1% sequentially. Revenue per day increased year over year primarily due to increased Medicare reimbursement rates partially offset by the resumption of sequestration and patient mix.

Adjusted EBITDA decreased year over year primarily due to higher cost of services resulting from increased labor costs. Cost per day increased year over year primarily due to increased labor costs related to the implementation of the new case management model, including costs associated with dedicated on-call and triage nurses, increased contract labor, and an increase in employee group medical claims.

GUIDANCE

The Company reaffirmed its full-year 2023 guidance as follows:

Full-year 2023		Guidance
*Net Service Revenue*		between $1,110 and $1,140 million
*Adjusted EBITDA*		between $125 and $140 million
*Adjusted EPS*		between $0.50 and $0.89

For additional considerations regarding the Company’s 2023 guidance ranges, see the supplemental information posted on the Company’s website at http://investors.ehab.com. See also “Other Information” below for an explanation of why the Company does not provide guidance for comparable GAAP measures for adjusted EBITDA and adjusted EPS.

CONFERENCE CALL INFORMATION

The Company will host an investor conference call at 10 AM Eastern Time on May 10, 2023 to discuss its results for the first quarter of 2023. To access the live call by phone, dial toll-free (888) 660-6150 or international (929) 203-0843; the conference ID is 5248158. A simultaneous webcast of the call, along with supplemental information, may be accessed by visiting http://investors.ehab.com. Following the call, a replay will be available at the same location.

ABOUT ENHABIT HOME HEALTH & HOSPICE

Enhabit Home Health & Hospice (Enhabit, Inc.) is a leading national home health and hospice provider working to expand what's possible for patient care in the home. Enhabit’s team of clinicians supports patients and their families where they are most comfortable, with a nationwide footprint spanning 253 home health locations and 107 hospice locations across 34 states. Enhabit leverages advanced technology and compassionate teams to deliver extraordinary patient care. For more information, visit ehab.com.

OTHER INFORMATION

Note regarding presentation of non-GAAP financial measures

The financial data contained in the press release and supplemental information includes non-GAAP financial measures as defined in Regulation G under the Securities Exchange Act of 1934, including adjusted EBITDA, adjusted EBITDA margin, leverage ratios, adjusted EPS, and adjusted free cash flow. Reconciliations of these non-GAAP financial measures to the most directly comparable financial measures calculated in accordance with GAAP are presented on the attached schedules. In reliance on the exception provided by Item 10(e)(1)(i)(B) of Regulation S-K, reconciliation of our guidance of adjusted EBITDA and adjusted EPS to their corresponding GAAP measures is not provided because the Company is unable to provide such reconciliation, without unreasonable effort, due to the inherent difficulty in predicting, with reasonable certainty, the future impact of items that are outside the control of the Company or otherwise non-indicative of its ongoing operating performance. Such items include, but are not limited to, gains or losses related to hedging instruments; loss on early extinguishment of debt; adjustments to its income tax provision (such as valuation allowance adjustments and settlements of income tax claims); and items related to corporate and facility restructurings. For the same reasons, the Company is unable to address the probable significance of the unavailable information.

Note regarding presentation of same-store comparisons

The Company uses “same-store” comparisons to explain the changes in certain performance metrics and line items within its financial statements. Same-store comparisons are calculated based on home health and hospice locations open throughout both the full current period and the immediately prior period presented. These comparisons include the financial results of market consolidation transactions in existing markets, as it is difficult to determine, with precision, the incremental impact of these transactions on the Company’s results of operations.

Enhabit, Inc. and Subsidiaries Condensed Consolidated Statements of Income (Unaudited)

	Three Months Ended March 31,
	2023		2022
	(In Millions, Except Per Share Data)
Net service revenue	$	265.1	$	274.3
Cost of service, excluding depreciation and amortization		132.6		129.7
General and administrative expenses		110.5		100.7
Depreciation and amortization		7.8		8.5
Operating income		14.2		35.4
Interest expense and amortization of debt discounts and fees		9.5		—
Income before income taxes and noncontrolling interests		4.7		35.4
Income tax expense		1.5		8.7
Net income		3.2		26.7
Less: Net income attributable to noncontrolling interests		0.5		0.6
Net income attributable to Enhabit, Inc.	$	2.7	$	26.1

Weighted average common shares outstanding:
Basic		49.8		49.6
Diluted		50.1		49.6

Earnings per common share:
Basic earnings per share attributable to Enhabit, Inc. common stockholders	$	0.05	$	0.53
Diluted earnings per share attributable to Enhabit, Inc. common stockholders	$	0.05	$	0.53

Enhabit, Inc. and Subsidiaries Condensed Consolidated Balance Sheets (Unaudited)

	March 31, 2023		December 31, 2022
	(In Millions)
Assets
Current assets:
Cash and cash equivalents	$	37.6	$	22.9
Restricted cash		2.0		4.3
Accounts receivable		156.5		149.6
Income tax receivable		4.3		11.4
Prepaid expenses and other current assets		12.2		23.6
Total current assets		212.6		211.8
Property and equipment, net		19.0		20.4
Operating lease right-of-use assets		45.8		42.0
Goodwill		1,147.5		1,144.8
Intangible assets, net		97.1		102.6
Other long-term assets		5.0		5.2
Total assets	$	1,527.0	$	1,526.8
Liabilities and Stockholders’ Equity
Current liabilities:
Current portion of long-term debt	$	22.7	$	23.1
Current operating lease liabilities		11.6		14.0
Accounts payable		6.2		3.8
Accrued payroll		47.7		35.5
Refunds due patients and other third-party payors		8.0		8.3
Accrued medical insurance		7.5		7.5
Other current liabilities		31.9		40.7
Total current liabilities		135.6		132.9
Long-term debt, net of current portion		549.7		560.0
Long-term operating lease liabilities		34.2		28.1
Deferred income tax liabilities		28.5		28.6
Other long-term liabilities		3.0		1.9
		751.0		751.5
Commitments and contingencies
Redeemable noncontrolling interests		5.1		5.2
Stockholders’ equity:
Enhabit, Inc. stockholders’ equity:		744.3		741.7
Noncontrolling interests		26.6		28.4
Total stockholders’ equity		770.9		770.1
Total liabilities and stockholders’ equity	$	1,527.0	$	1,526.8

Enhabit, Inc. and Subsidiaries Condensed Consolidated Cash Flows (Unaudited)

	Three Months Ended March 31,
	2023			2022
	(In Millions)
Cash flows from operating activities:
Net income	$	3.2		$	26.7
Adjustments to reconcile net income to net cash provided by operating activities—
Depreciation and amortization		7.8			8.5
Amortization of debt related costs		0.3			—
Stock-based compensation		1.5			1.3
Deferred tax expense (benefit)		0.3			(0.2	)
Other, net		—			(0.2	)
Changes in assets and liabilities, net of acquisitions—
Accounts receivable		(6.7	)		(0.1	)
Prepaid expenses and other assets		18.1			(1.6	)
Accounts payable		2.3			(0.6	)
Accrued payroll		12.2			(1.6	)
Other liabilities		(9.4	)		9.2
Net cash provided by operating activities		29.6			41.4
Cash flows from investing activities:
Acquisition of businesses, net of cash acquired		(2.8	)		—
Purchases of property and equipment		(0.6	)		(2.3	)
Other, net		0.2			0.9
Net cash used in investing activities		(3.2	)		(1.4	)
Cash flows from financing activities:
Principal payments on term loan		(5.0	)		—
Payments on revolving credit facility		(5.0	)		—
Distributions paid to noncontrolling interests of consolidated affiliates		(2.5	)		(0.5	)
Principal payments under finance lease obligations		(1.0	)		(1.4	)
Contributions from Encompass		—			23.5
Distributions to Encompass		—			(55.8	)
Contributions from noncontrolling interests of consolidated affiliates		—			7.4
Other		(0.5	)
Net cash used in financing activities		(14.0	)		(26.8	)
Increase in cash, cash equivalents, and restricted cash		12.4			13.2
Cash, cash equivalents, and restricted cash at beginning of year		27.2			8.0
Cash, cash equivalents, and restricted cash at end of year	$	39.6		$	21.2

Enhabit, Inc. and Subsidiaries Supplemental Information Adjusted Earnings Per Share

	Q1
	2023		2022
Earnings per share, as reported	$	0.05	$	0.53
Adjustments, net of tax:
Income tax adjustments		0.01		—
Unusual or nonrecurring items that are not typical of ongoing operations⁽¹⁾		0.03		0.03
Adjusted earnings per share⁽²⁾	$	0.09	$	0.56

(1)		Unusual or nonrecurring items include costs associated with the strategic alternatives review, shareholder activism defense, and non-routine litigation.
(2)		Adjusted EPS may not sum due to rounding.

Enhabit, Inc. and Subsidiaries Supplemental Information Adjusted Earnings Per Share

	Q1 QTD
	2023
				Adjustments
	As Reported			Income Tax Adjustments		Unusual or nonrecurring items that are not typical of ongoing operations			As Adjusted
	(In Millions, Except Per Share Amounts)
Adjusted EBITDA⁽¹⁾	$	25.3		$	—	$	—		$	25.3
Depreciation and amortization		(7.8	)		—		—			(7.8	)
Interest expense and amortization of debt discounts and fees		(9.5	)		—		—			(9.5	)
Gain on disposal of assets		—			—		—			—
Stock-based compensation		(1.5	)		—		—			(1.5	)
Unusual or nonrecurring items that are not typical of ongoing operations⁽²⁾		(2.3	)		—		2.3			—
Income before income tax expense		4.2			—		2.3			6.5
Provision for income tax expense		(1.5	)		0.4		(0.6	)		(1.7	)
Net income attributable to Enhabit	$	2.7		$	0.4	$	1.7		$	4.8
Diluted earnings per share⁽³⁾	$	0.05		$	0.01	$	0.03		$	0.09
Diluted shares used in calculation		50.1

(1)		See reconciliation of net income to adjusted EBITDA.
(2)		Unusual or nonrecurring items include costs associated with the strategic alternatives review, shareholder activism defense, and non-routine litigation.
(3)		Adjusted EPS may not sum due to rounding.

Enhabit, Inc. and Subsidiaries Supplemental Information Adjusted Earnings Per Share

	Q1 QTD
	2022
				Adjustments
	As Reported			Unusual or nonrecurring items that are not typical of ongoing operations			As Adjusted
	(In Millions, Except Per Share Amounts)
Adjusted EBITDA⁽¹⁾	$	47.0		$	—		$	47.0
Depreciation and amortization		(8.5	)		—			(8.5	)
Interest expense and amortization of debt discounts and fees		—			—			—
Gain on disposal of assets		0.1			—			0.1
Stock-based compensation		(1.3	)		—			(1.3	)
Stock-based compensation included in overhead allocation		(0.5	)		—			(0.5	)
Unusual or nonrecurring items that are not typical of ongoing operations⁽²⁾		(2.0	)		2.0			—
Income before income tax expense		34.8			2.0			36.8
Provision for income tax expense		(8.7	)		(0.5	)		(9.2	)
Net income attributable to Enhabit	$	26.1		$	1.5		$	27.6
Diluted earnings per share⁽³⁾	$	0.53		$	0.03		$	0.56
Diluted shares used in calculation		49.6

(1)		See reconciliation of net income to adjusted EBITDA.
(2)		Unusual or nonrecurring items include costs associated with the strategic alternatives review, shareholder activism defense, and non-routine litigation.
(3)		Adjusted EPS may not sum due to rounding.

Enhabit, Inc. and Subsidiaries Supplemental Information Reconciliation of Net Income to Adjusted EBITDA

	Three Months Ended March 31,
	2023			2022
	(In Millions)
Net Income	$	3.2		$	26.7
Income tax expense		1.5			8.7
Interest expense and amortization of debt discounts and fees		9.5			—
Depreciation and amortization		7.8			8.5
(Gain) loss on disposal or impairment of assets		—			(0.1	)
Stock-based compensation		1.5			1.3
Stock-based compensation included in overhead allocation		—			0.5
Net income attributable to noncontrolling interests		(0.5	)		(0.6	)
Unusual or nonrecurring items that are not typical of ongoing operations⁽¹⁾		2.3			2.0
Adjusted EBITDA	$	25.3		$	47.0

(1)

Unusual or nonrecurring items include costs associated with the strategic alternatives review, shareholder activism defense, and non-routine litigation.

Reconciliation of Net Cash Provided by Operating Activities to Adjusted EBITDA

	Three Months Ended March 31,
	2023			2022
	(In Millions)
Net cash provided by operating activities	$	29.6		$	41.4
Interest expense and amortization of debt discounts and fees		9.5			—
Equity in net income of nonconsolidated affiliates		—			—
Net income attributable to noncontrolling interests in continuing operations		(0.5	)		(0.6	)
Distributions from nonconsolidated affiliates		—			(0.2	)
Current portion of income tax expense		1.2			8.9
Change in assets and liabilities		(16.5	)		(5.3	)
Unusual or nonrecurring items that are not typical of ongoing operations⁽¹⁾		2.3			2.0
Stock-based compensation included in overhead allocation		—			0.5
Other		(0.3	)		0.3
Adjusted EBITDA	$	25.3		$	47.0

(1)

Unusual or nonrecurring items include costs associated with the strategic alternatives review, shareholder activism defense, and non-routine litigation.

Enhabit, Inc. and Subsidiaries Supplemental Information Reconciliation of Net Cash Provided by Operating Activities to Adjusted Free Cash Flow

	Q1
($ in millions)	2023			2022
Net cash provided by operating activities	$	29.6		$	41.4
Capital expenditures for maintenance		(0.6	)		(2.3	)
Distributions paid to noncontrolling interests of consolidated affiliates		(2.5	)		(0.5	)
Other working capital adjustments		(0.5	)		(0.5	)

Items non-indicative of ongoing operating performance:
Stock-based compensation included in overhead allocation		—			0.5
Unusual or nonrecurring items that are not typical of ongoing operations⁽¹⁾		2.3			2.0
Adjusted free cash flow	$	28.3		$	40.6

(1)

Unusual or nonrecurring items include costs associated with the strategic alternatives review, shareholder activism defense, and non-routine litigation.

FORWARD-LOOKING STATEMENTS

Statements contained in this press release which are not historical facts, such as those relating to future events, projections, financial guidance, legislative or regulatory developments, strategy or growth opportunities, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All such estimates, projections, and forward-looking information speak only as of the date hereof, and Enhabit undertakes no duty to publicly update or revise such forward-looking information, whether as a result of new information, future events, or otherwise. Such forward-looking statements are necessarily estimates based upon current information and involve a number of risks and uncertainties. Actual events or results may differ materially from those anticipated in these forward-looking statements as a result of a variety of factors. While it is impossible to identify all such factors, factors which could cause actual events or results to differ materially from those estimated by Enhabit include, but are not limited to, our ability to execute on our strategic plans, regulatory and other developments impacting the markets for our services, changes in reimbursement rates, general economic conditions, our ability to attract and retain key management personnel and healthcare professionals, potential disruptions or breaches of our or our vendors’ information systems, the outcome of litigation, our ability to successfully complete and integrate de novo developments, acquisitions, investments, and joint ventures, and our ability to control costs, particularly labor and employee benefit costs. Our Form 10K and subsequent quarterly reports on Form 10-Q, each of which can be found on the Company’s website at http://investors.ehab.com and the SEC’s website at www.sec.gov, discuss other risks and factors that could cause actual results to differ materially from those expressed or implied by any forward-looking statement in this press release. We urge you to consider all of the risks, uncertainties and factors identified above or discussed in such reports carefully in evaluating the forward-looking statements in this press release.

Stock Quote

Last Trade:	US$7.56
Daily Change:	0.09 1.20
Daily Volume:	376,750
Market Cap:	US$380.120M

November 06, 2024 Enhabit Reports Third Quarter 2024 Financial Results August 06, 2024 Enhabit Reports Second Quarter 2024 Financial Results July 15, 2024 Enhabit Releases Certain Preliminary Second Quarter 2024 Results July 01, 2024 Enhabit Releases Investor Presentation Demonstrating Execution of Clear Growth Strategy and Path to Unlock Shareholder Value May 08, 2024 Enhabit Reports First Quarter 2024 Financial Results LOAD MORE NEWS

Featured Stock

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE